WithdrawnPhase 2Phase 3ACTRN12611000274976

Adipose-derived stem cells in patients with knee osetoarthritis: A randomised controlled trial evaluating pain, function and cartillage repair


Sponsor

Kade Paterson

Enrollment

60 participants

Start Date

May 15, 2011

Study Type

Interventional

Conditions

Summary

Knee osteoarthritis (OA) is a progressive degenerative condition of articular cartilage and subchondral bone that leads to significant physical and psychological disability, and adversely affects daily function and quality of life. Current treatment of knee OA is associated with limitations and side effects that restrict their ability to effectively treat the symptoms of the condition and stop its progression. Recent research has demonstrated that Human adipose-derived stem cells (ADSCs) are safe for use in Humans and can differentiate into cartilage and bone, suggesting a potential treatment in osteoarthritis. This study aims to assess the changes in pain, cartilage and bone appearance, activity levels and lower extremity functional ability of patients with knee OA following intra-articular ADSC injection compared to usual treatment of Hylan G-F 20 (Synvisc [Registered Trademark]).


Eligibility

Sex: Both males and femalesMin Age: 18 YearssMax Age: 80 Yearss

Plain Language Summary

Simplified for easier understanding

This trial tests whether injecting stem cells derived from the patient's own fat tissue into the knee joint can reduce pain and help repair cartilage in people with knee osteoarthritis. Participants must be 18 to 80 years old with significant knee pain. People with inflammatory joint disease, cancer, pregnancy, or who are immunosuppressed are not eligible.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Three injections each of 5ml stromal vascular fraction containing adipose-derived stem cells two months apart. Time-points for injections: 1) initial injection, 2) two months following initial injecti

Three injections each of 5ml stromal vascular fraction containing adipose-derived stem cells two months apart. Time-points for injections: 1) initial injection, 2) two months following initial injection and 3) four months following initial injection. This results in a total treatment duration of five months.


Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12611000274976


Related Trials